Aberrant Gene Expression Prostate Carcinoma
This trial is active, not recruiting.
|Start date||April 1995|
|End date||April 2020|
|Trial size||5000 participants|
|Trial identifier||NCT00868803, LCID1995-014|
The goal of the study is to gain a better understanding of the molecular changes responsible for causing prostate cancer and that examination of tissue and blood samples will help in the development of improved screening and therapeutic approaches.
Male participants of any age.
Inclusion Criteria: - Diagnosed prostate cancer undergoing prostatectomy - Suspicion of prostate cancer undergoing biopsy - negative biopsy - Health volunteer (control group) - blood sample for PSA Exclusion Criteria: - Patients not fitting the inclusion criteria
|Official title||Identification of Aberant Gene Expression in Human Prostatic Carcinoma|
|Principal investigator||John A Libertino, M.D.|
|Description||The goal of this study is to identify novel genetic elements that are aberantly expressed throughout prostatic neoplastic progression. The approaches proposed exploit the known familial arm of prostatic cancer, using established molecular genetic approaches, and extend these studies to sporadic prostatic cancer using a novel technique of differential display. Application of the latter technique to colon cancer in the American population establishes this tumor type as a high priority for scientific investigation and this study is part of an initiative to address this problem. Presently the studies in the field of prostate are under-represented. The collection of tissue samples from patients diagnosed with prostate cancer. Patients will also provide a blood sample at the time of their surgery and potentially post-op from 6 mos to 5 years. Samples will also be obtained from patients who's biopsy turns out to be non-prostate cancer. These samples will be obtained shortly following the biopsy out to 6 months after the biopsy.|
Call for more information